Per Rathenborg

1.7k citations

18 papers · 1.1k indexed · 1 hit paper · h-index 11

Impact in

Pulmonary and Respiratory Medicine top 2%
- Prostate Cancer Treatment and Research
- Prostate Cancer Diagnosis and Treatment
Cancer Research top 5%
- Cancer, Lipids, and Metabolism

Papers in ⓘ

Pulmonary and Respiratory Medicine 16
- Prostate Cancer Treatment and Research 15
- Prostate Cancer Diagnosis and Treatment 5
Cancer Research 10
- Cancer, Lipids, and Metabolism 9

Co-authors: Fred Saad (5 shared papers)Neal D. Shore (6 shared papers)De Phung (8 shared papers)Andrew Krivoshik (5 shared papers)Karim Fizazi (4 shared papers)Eren Demirhan (4 shared papers)Katharina Modelska (4 shared papers)Maha Hussain (4 shared papers)
Journals: Journal of Clinical Oncology (7 papers)The Journal of Urology (2 papers)New England Journal of Medicine (1 paper)British Journal of Urology (1 paper)The Lancet Oncology (1 paper)
Partner nations: Denmark United States Netherlands

In The Last Decade

Per Rathenborg

17 papers receiving 1.1k citations

Hit Papers

align trajectories log scale

Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer 2018 · 677 citations

Peers

Countries citing papers authored by Per Rathenborg

Since Specialization

Citations

This map shows the geographic impact of Per Rathenborg's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Per Rathenborg with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Per Rathenborg more than expected).

Fields of papers citing papers by Per Rathenborg

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Per Rathenborg. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Per Rathenborg. The network helps show where Per Rathenborg may publish in the future.

Co-authors

The 25 scholars most cited alongside Per Rathenborg, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Per Rathenborg Line = papers co-authored together Per Rathenborg links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

18 of 18 papers shown

#	Work
1	Enzalutamide in Men with Nonmetastatic, Castration-Resistant Prostate Cancer New England Journal of Medicine ·Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal D. Shore, Ubirajara Ferreira, Petro Ivashchenko, Eren Demirhan, Katharina Modelska, De Phung, Andrew Krivoshik, Cora N. Sternberg Hit paper breakdown →	2018	677
2	Phase III Trial of PROSTVAC in Asymptomatic or Minimally Symptomatic Metastatic Castration-Resistant Prostate Cancer Journal of Clinical Oncology ·James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Fred Saad, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Frank Priou, Niels Christian Langkilde, A I Novikov, Philip W. Kantoff	2019	183
3	Enzalutamide monotherapy in hormone-naive prostate cancer: primary analysis of an open-label, single-arm, phase 2 study The Lancet Oncology ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiří Heráček, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Mohammad Hirmand, Matthew R. Smith	2014	71
4	Enzalutamide treatment in patients with metastatic castration-resistant prostate cancer progressing after chemotherapy and abiraterone acetate Scandinavian Journal of Urology ·Frederik Birkebæk Thomsen, Martin Andreas Røder, Per Rathenborg, Klaus Brasso, Michael Borre, Peter Iversen	2013	57
5	Long-term Efficacy and Safety of Enzalutamide Monotherapy in Hormone-naïve Prostate Cancer: 1- and 2-Year Open-label Follow-up Results European Urology ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiří Heráček, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Benoît Baron, Mohammad Hirmand, Matthew R. Smith	2015	34
6	PROSPER: A phase 3, randomized, double-blind, placebo (PBO)-controlled study of enzalutamide (ENZA) in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC). Journal of Clinical Oncology ·Maha Hussain, Karim Fizazi, Fred Saad, Per Rathenborg, Neal D. Shore, Eren Demirhan, Katharina Modelska, De Phung, Andrew Krivoshik, Cora N. Sternberg	2018	26
7	Fatal pulmonary embolism associated with surgery. An autopsy study. PubMed ·Ole Hauch, Jørgensen Ln, Khattar Sc, Teglbjaerg Cs, Wåhlin Ab, Per Rathenborg, Torben Jørgensen	1991	20
8	Long-Term Antitumor Activity and Safety of Enzalutamide Monotherapy in Hormone Naïve Prostate Cancer: 3-Year Open Label Followup Results The Journal of Urology ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiří Heráček, Benoît Baron, Andrew Krivoshik, Mohammad Hirmand, Matthew R. Smith	2017	20
9	Ease of removal of thermo‐expandable prostate stents British Journal of Urology ·Neil Barber, Alison Roodhouse, Per Rathenborg, Jørgen Nordling, Brian W. Ellis	2005	14
10	Efficacy and safety of enzalutamide (ENZA) monotherapy in hormone-naive prostate cancer (HNPC). Journal of Clinical Oncology ·Matthew R. Smith, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Edwina Baskin-Bey, Frank Perabo, De Phung, Bertrand Tombal	2013	12
11	Results of PROSPECT: A randomized phase 3 trial of PROSTVAC-V/F (PRO) in men with asymptomatic or minimally symptomatic metastatic, castration-resistant prostate cancer. Journal of Clinical Oncology ·James L. Gulley, Michael Borre, Nicholas J. Vogelzang, Siobhan Ng, Neeraj Agarwal, Chris Parker, David Pook, Per Rathenborg, Thomas W. Flaig, Joan Carles, Neal D. Shore, Liddy Chen, Christopher R. Heery, Winald R. Gerritsen, Frank Priou, Philip W. Kantoff	2018	10
12	Enzalutamide monotherapy: Phase II study results in patients with hormone-naive prostate cancer. Journal of Clinical Oncology ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Axel Heidenreich, Peter Iversen, Edwina Baskin-Bey, Frank Perabo, De Phung, Matthew R. Smith	2013	4
13	[Presence of pulmonary emboli in Danish autopsy material]. PubMed ·Jørgensen Ln, Ole Hauch, Teglbjaerg Cs, Wåhlin Ab, Per Rathenborg, Khattar Sc, Torben Jørgensen	1989	4
14	Biochemical response to enzalutamide therapy in patients with mCRPC following docetaxel and abiraterone treatment. Journal of Clinical Oncology ·M. Andreas Roeder, Frederik Birkebæk Thomsen, Klaus Brasso, Per Rathenborg, Michael Borre, Peter Iversen	2014	4
15	Enzalutamide monotherapy: Extended follow-up of a phase II study in hormone-naive prostate cancer patients. Journal of Clinical Oncology ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Hendrik Van Poppel, Axel Heidenreich, Peter Iversen, Johan Braeckman, Jiří Heráček, Edwina Baskin-Bey, Taoufik Ouatas, Frank Perabo, De Phung, Matthew R. Smith	2014	3
16	674 Enzalutamide monotherapy: Results from a phase 2 study in hormone naive prostate cancer patients European Urology Supplements ·Bertrand Tombal, Michael Borre, Per Rathenborg, Patrick Werbrouck, Axel Heidenreich, Peter Iversen, Edwina Baskin-Bey, Frank Perabo, D. Phung, Mitchell R. Smith	2013	1
17	PD10-09 THE PROSPER TRIAL: CHEMOTHERAPY-RELATED ENDPOINTS IN PATIENTS WITH NONMETASTATIC CASTRATION-RESISTANT PROSTATE CANCER TREATED WITH ENZALUTAMIDE The Journal of Urology ·Neal D. Shore, Fred Saad, Maha Hussain, Karim Fizazi, Per Rathenborg, Eren Demirhan, Katharina Modelska, De Phung, Andrew Krivoshik, Cora N. Sternberg	2018	1
18	Prostate-specific antigen (PSA) response in men with nonmetastatic castration-resistant prostate cancer (M0 CRPC) treated with enzalutamide (ENZA): Results from PROSPER European Urology Supplements ·Cora N. Sternberg, Karim Fizazi, Fred Saad, Per Rathenborg, Neal D. Shore, Eren Demirhan, Katharina Modelska, D. Phung, Andrew Krivoshik, Maha Hussain	2018	0

About Per Rathenborg

Per Rathenborg is a scholar working on Pulmonary and Respiratory Medicine, Cancer Research, Radiology, Nuclear Medicine and Imaging, Endocrinology, Diabetes and Metabolism and Internal Medicine, having authored 18 papers that have together received 1.1k indexed citations. Recurring topics across this work include Prostate Cancer Treatment and Research (15 papers), Cancer, Lipids, and Metabolism (9 papers), Hormonal and reproductive studies (5 papers), Prostate Cancer Diagnosis and Treatment (5 papers), Radiopharmaceutical Chemistry and Applications (5 papers), Venous Thromboembolism Diagnosis and Management (2 papers), Protein Degradation and Inhibitors (1 paper) and Autopsy Techniques and Outcomes (1 paper). The work is most often cited by research in Pulmonary and Respiratory Medicine (923 citations), Cancer Research (325 citations), Radiology, Nuclear Medicine and Imaging (308 citations), Oncology (309 citations) and Endocrinology, Diabetes and Metabolism (182 citations). Per Rathenborg has collaborated with scholars based in Denmark, United States and Netherlands. Frequent co-authors include Fred Saad, Neal D. Shore, De Phung, Andrew Krivoshik, Karim Fizazi, Eren Demirhan, Katharina Modelska, Maha Hussain, Cora N. Sternberg and Ubirajara Ferreira. Their work appears in journals such as Journal of Clinical Oncology, The Journal of Urology, New England Journal of Medicine, British Journal of Urology and The Lancet Oncology.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact